Parp Inhibitors Pipeline Insight

DelveInsight’s, “PARP Inhibitors– Pipeline Insights, 2022,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in PARP Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

PARP Inhibitors Understanding

PARP Inhibitors: Overview

PARP is a family of proteins loosely based on structural similarity and function. PARP proteins are composed of two ribose moieties and two phosphates per unit polymer. PARP1 and PARP2 are enzymes involved in a DNA repair pathway for SSBs called BER. The best-known PARP is PARP1. This enzyme was first reported in 1963. In 1980 Durkacz et al. proposed that modulating PARP1 might augment the effect of alkylator chemotherapy. PARP1 detects and binds to sites of single strand DNA damage via the DNA-binding domain. It then synthesizes poly (ADP) ribose (PAR) and transfers it to acceptor proteins. PAR recruits other repair proteins to the damaged DNA site. In the case of extreme DNA damage, as with ischemia, PARP1 hyperactivation induces depletion of NAD+ and ATP, resulting in cell death by necrosis or apoptosis. PAR is involved in double strand breaks (DSBs) repair as well. PAR recruits ATM, MRE11, and topoisomerase 1, which are involved in DSBs repair.

  • All current PARP inhibitors in development are thought to inhibit both PARP1 and PARP2. Though nicotinamide's activity in inhibiting PARP was first noted in 1971, the exploration of this class of agent has recently become extensive. The first generation of inhibitors included nicotinamide analogues.
  • In multiple PARPi-involved combination strategies, PARPi acts as sensitizers for chemotherapies, immunotherapies, and targeted therapies by limiting DNA damage repair. In addition, some targeted treatments such as MEK inhibitors could enhance the sensitivity of tumor cells and relieve the resistance to PARPi

PARP Inhibitors Emerging Drugs Chapters

This segment of the PARP Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

PARP Inhibitors Emerging Drugs

  • Pamiparib: BeiGene

Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies

Further product details are provided in the report……..

PARP Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different PARP Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:


  • Major Players working on PARP Inhibitors

There are approx. 30+ key companies which are developing the PARP Inhibitors. The companies which have their PARP Inhibitors drug candidates in the most advanced stage, i.e. phase III include, BeiGene.


  • Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


PARP Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.


PARP Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses PARP Inhibitors therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PARP Inhibitors drugs.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence PARP Inhibitors R&D. The therapies under development are focused on novel approaches for PARP Inhibitors.
  • July 2020: Oncology Venture announced that it has secured the remaining ownership in its priority PARP inhibitor (2X-121) program along with its 2X-111 program, by acquiring all outstanding shares in Oncology Venture US Inc. (formerly 2X Oncology, Inc.) from its external shareholders and warrantholders. As a result of the transaction, the Company now has 100 % ownership of 2X-121, which is being clinically developed as an anti-cancer therapeutic, as well as being tested as an anti-viral agent against COVID-19. Similarly, the Company now has 100% ownership of 2X-111, which is being clinically developed as an anti-cancer therapeutic via a recently announced license agreement with Smerud Medical Research International.


PARP Inhibitors Report Insights

  • PARP Inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs


PARP Inhibitors Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

  • How many companies are developing PARP Inhibitors drugs?
  • How many PARP Inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for PARP Inhibitors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the PARP Inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for PARP Inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • TESARO
  • AstraZeneca
  • Sun BioPharma
  • Eisai Co
  • BeiGene
  • IMPACT Therapeutics
  • Ribon Therapeutics

Key Products

  • Niraparib  
  • Olaparib
  • SBP 101
  • 2X 121

 

Introduction

Executive Summary

PARP Inhibitors: Overview

• Structure

• Mechanism of Action

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type

• Assessment by Stage and Product Type

• Assessment by Route of Administration

• Assessment by Stage and Route of Administration

• Assessment by Molecule Type

• Assessment by Stage and Molecule Type

PARP Inhibitors – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

• PARP Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends

PARP Inhibitors Collaboration Deals

• Company-Company Collaborations (Licensing / Partnering) Analysis

• Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

• Comparative Analysis

Pamiparib: BeiGene

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

Drug Name: Company Name

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

• Comparative Analysis

Drug Name: Company Name

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

PARP Inhibitors Key Companies

PARP Inhibitors Key Products

PARP Inhibitors- Unmet Needs

PARP Inhibitors- Market Drivers and Barriers

PARP Inhibitors- Future Perspectives and Conclusion

PARP Inhibitors Analyst Views

PARP Inhibitors Key Companies

Appendix

List of Tables

 Table 1 Total Products for PARP Inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List of Figures

 Figure 1 Total Products for PARP Inhibitors

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

• TESARO

• AstraZeneca

• Sun BioPharma

• Eisai Co

• BeiGene

• IMPACT Therapeutics

• Ribon Therapeutics

Forward to Friend

Need A Quote